Watson W. Mark 4

What Happened Watson W. Mark, a director of Vaxart, was awarded two equity grants on 2026-07-16: 39,400 shares reported as acquired (grant A) and 78,700 derivative shares (grant A, derivative). Both grants show an acquisition price of $0.00 (no cash paid at grant). At the reported grant price the transaction value is $0, though market value at grant is not provided in the filing.

Key Details

• Transaction date: 2026-07-16; Form 4 filed 2026-07-17 (timely filing).
• Grants: 39,400 shares (direct award) and 78,700 derivative shares (likely stock option/RSU-like award per footnote).
• Reported price: $0.00 for both grants (no cash exchanged at grant).
• Vesting: Both awards vest on the earlier of the date immediately prior to the 2027 annual meeting or July 16, 2027 (first anniversary of the grant) — see footnotes F1 and F2.
• Shares owned after the transaction: not disclosed in the provided excerpt.
• Transaction type: Award/Grant (code A); derivative award explained in footnote (not exercised or sold).

Context These are grants/awards, not open-market purchases or sales — common for executive/director compensation and intended to align incentives rather than signal immediate buying/selling. The derivative portion appears to be subject to vesting (per footnote wording referencing an option); nothing in the filing indicates exercise, sale, or tax-withholding actions.